Regeneron and Sanofi expand their antibody alliance with four new drug candidates, FDA approves Camzyos for adolescents with obstructive hypertrophic cardiomyopathy, and Michael Abrams questions digital health's savings claims to employers.
Commentary|Podcasts|October 26, 2023
DCT Opportunities in Clinical Research
Author(s)Miranda Schmalfuhs
A discussion of the biggest digital trends in clinical research, how COVID-19 impacted digital use for sponsors/CROs, what the future of DCT services looks like, and more.
Advertisement
Edward Triebell, Commercial Executive Director for MRN Technologies, discusses the biggest digital trends in clinical research right now, how COVID-19 impacted the use of digital within sponsors and CROs, what the future of DCT services looks like, and more.
About the speaker
Edward Triebell is the Executive Director of Digital Health at Medical Research Network (MRN) and leads their strategy on empowering the use of digital technology in MRN’s Decentralized Clinical Trials services.
Mr. Triebell has been on the forefront of disruptive innovations in the development and application of digital technology for companies in the telecommunications, software, and healthcare industries. He started his career in design engineering and then transitioned into project engineering, program management, and sales eventually running global sales and marketing teams for technology focused enterprises, providing a wide lens on the requirements, development and launch of successful digital products and services.
For the past several years, Mr. Triebell has been involved in equity funded strategic roles. His most recent role pivoted an Internet of Things (IoT) software platform into an eCOA solution for successful acquisition by a CRO.
Within the healthcare industry, Mr. Triebell has been involved with programs including a telemedicine network for the Mayo Clinic network of hospitals to accomplish remote diagnosis and surgical treatments with high resolution imaging/videos, RFID solutions for patient tracking within Emergency Departments as well as audited tracking of patient biological samples and outsourcing radiological contouring for cancer treatments using a joint venture with China’s leading Cancer hospital.
Mr. Triebell earned his bachelor’s degree in electrical engineering and completed graduate coursework for his dual master’s degree in electrical engineering/engineering management from Florida Institute of Technology. He also completed an Executive Management program at the Wharton School of Business.
About the Pharm Exec Podcast
The editors of Pharmaceutical Executivebring you the latest commercial insights to master the science of success. Podcast episodes examine current trends, key conferences, and critical topics in the bio/pharmaceutical industry.
Listen to this podcast on
Advertisement
Related to this article
Novo Nordisk data show real-world weight loss after switching to its oral semaglutide pill, FDA's peptide rulemaking stalls while its enforcement arm targets compounded peptide sellers, and Avi Pardo flags a compliance blind spot in field teams' text messages with doctors.
New U.S. guidance carves out tariff exemptions for specialty pharmaceuticals, Pharming's Fabrice Chouraqui steps down as CEO amid a board rift, and a dealmaking roundup covers Hengrui Pharma's licensing agreement with Novo Nordisk and AstraZeneca's investment in Summit Therapeutics.
Merck licenses a preclinical KRAS G12D inhibitor from SciBrunch, FDA approves Olumiant, Juvmo, and Atebrioz across three separate indications, and Matthew Montes de Oca makes the case for compounding pharmacies to set their own safety standards.
FDA approves Merck and Eisai's Welireg-Lenvima combination for advanced kidney cancer, a platform-deal roundup covers Novo Nordisk, Genentech, and Roche's tie-ups with Nanexa, Earendil Labs, and Atavistik Bio, and Ron Lanton examines the fight to regulate pharmacy benefit managers.
InnoCare Pharma and Eli Lilly ink a multibillion-dollar research collaboration, FDA approves Lilly's once-weekly insulin Onswik for type 2 diabetes, and Jen Lamppa talks fixing clinical trial patient enrollment with real-world data.
EVERSANA's Jen Norton talks about how AI is reshaping market access strategy, a new analysis from MIT and Harvard Business School names clinical data harmonization as the real barrier to enterprise AI adoption in life sciences, and Novo Nordisk's CEO says he's open to a direct NYSE listing.
Nine major European drugmakers warn the region risks losing pharma investment, Novartis licenses a preclinical radioligand therapy asset from BoomRay Pharmaceuticals, and Rafaat Rahmani argues that the costliest competitive intelligence failure is missing the moment a strategic assumption goes wrong.
Advertisement
Advertisement
Trending on PharmExec
1
Regeneron and Sanofi Expand Antibody Alliance with Four New Drugs
2
The Next Chapter in Metabolic Drug Development
3
New U.S. Guidance Lays Out Exemptions for 100% Tariffs: Report
4
As Peptide Rulemaking Stalls, FDA Enforcement Moves Forward
5